MOB.ST
Price:
$8.695
Market Cap:
$406.00M
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products in Europe, the United States, and internationally. It develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is headquartered in Bromma, Sweden.
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2011-05-26
Stock Exchange
STO
Ticker
MOB.ST
According to Moberg Pharma AB (publ)’s latest financial reports and current stock price. The company's current PE Ratio is -1.32. This represents a change of -97.07% compared to the average of -45.09 of the last 4 quarters.
The mean historical PE Ratio of Moberg Pharma AB (publ) over the last ten years is 9.01. The current -1.32 PE Ratio has changed -1565.17% with respect to the historical average. Over the past ten years (40 quarters), MOB.ST's PE Ratio was at its highest in in the December 2015 quarter at 3.79K. The PE Ratio was at its lowest in in the December 2016 quarter at -528.95.
Average
9.01
Median
7.63
Minimum
-14.25
Maximum
39.62
Discovering the peaks and valleys of Moberg Pharma AB (publ) PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 100.03%
Maximum Annual PE Ratio = 39.62
Minimum Annual Increase = -225.70%
Minimum Annual PE Ratio = -14.25
Year | PE Ratio | Change |
---|---|---|
2024 | -1.51 | -87.14% |
2023 | -11.73 | 4.66% |
2022 | -11.21 | -21.35% |
2021 | -14.25 | 100.03% |
2020 | -7.12 | -117.98% |
2018 | 39.62 | 37.39% |
2017 | 28.84 | 72.00% |
2016 | 16.77 | -31.34% |
2015 | 24.42 | -7.03% |
2014 | 26.27 | -225.70% |
The current PE Ratio of Moberg Pharma AB (publ) (MOB.ST) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-8.15
5-year avg
-9.16
10-year avg
9.01
Moberg Pharma AB (publ)’s PE Ratio is greater than Mendus AB (publ) (-2.08), greater than BioInvent International AB (publ) (-4.39), greater than Orexo AB (publ) (-2.54), greater than Oncopeptides AB (publ) (-1.50), less than Saniona AB (publ) (5.10),
Company | PE Ratio | Market cap |
---|---|---|
-2.08 | $258.85M | |
-4.39 | $2.05B | |
-2.54 | $534.14M | |
-1.50 | $421.68M | |
5.10 | $1.17B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Moberg Pharma AB (publ) using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Moberg Pharma AB (publ) or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Moberg Pharma AB (publ)'s PE Ratio?
How is the PE Ratio calculated for Moberg Pharma AB (publ) (MOB.ST)?
What is the highest PE Ratio for Moberg Pharma AB (publ) (MOB.ST)?
What is the 3-year average PE Ratio for Moberg Pharma AB (publ) (MOB.ST)?
What is the 5-year average PE Ratio for Moberg Pharma AB (publ) (MOB.ST)?
How does the current PE Ratio for Moberg Pharma AB (publ) (MOB.ST) compare to its historical average?